ClinicalTrials.gg
Not yet recruitingNCT07938203HIITing MitoQUpdated Nov 16, 2026

MitoQ Supplementation for Microvascular Health and Stroke Recovery

A Phase 2 interventional study of MitoQ and Placebo in Stroke and Stroke Recurrence, sponsored by Medical College of Wisconsin. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Medical College of Wisconsin · Phase 2, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies in Stroke by Medical College of Wisconsin — 7 open to participants now, 8 under way, none of them phase 3. Stroke · Medical College of Wisconsin.

Planned enrollment
7th of 17
50 · median 50
Started
2027
the only one that year
Phase 2
2 of 18
2 open now
Registered
18th of 18
by date

Among the 18 studies in Stroke by Medical College of Wisconsin, this one is the 7th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2027, is one of 2 in phase 2, and was the 18th registered.

Stroke

8,268 studies on the registry are indexed under Stroke; 2,062 are open to participants now.

Browse Stroke studies →

Open to participants now

7 of the 18 studies in Stroke by Medical College of Wisconsin are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 696 (49%) set no upper age limit and 282 (20%) stop at 75 or younger; 77 take children under 18; 196 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Stroke by Medical College of Wisconsin, or all of them as a file.
02

Study summary

Stroke survivors have compromised vascular function which may contribute to secondary stroke risk, cardiovascular disease, and may limit their exercise tolerance. Preliminary data shows an antioxidant supplement called MitoQ may improve vascular function and muscle activity in individuals post-stroke.

03

Conditions studied

  • Stroke
  • Stroke Recurrence

Browse trials for

Keywords

  • Blood Flow
  • High Intensity Exercise
  • Microvascular Health
  • Flow Mediated Dilation
  • Antioxidant
  • Supplement
  • Reactive Oxygen Species
  • Walking
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-85 years
  • Cortical or subcortical stroke ≥ 6 months ago
  • Follows 2-step command
  • English speaking

Exclusion criteria

Exclusion Criteria:

  • Unable to walk 10 meters without physical assistance (able to use assistive device)
  • Unable to perform HIIE
  • Head Trauma \< 6 months ago
  • Resting BP ≥ 180/100 mmHg
  • Heart attack \<1 year ago.
  • Pregnant and/or breastfeeding
  • History of other neurological disease
  • Unable to obtain MCAv signal
  • Other significant medical condition likely to influence study or jeopardize safety as assessed by Primary Investigator
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Antioxidant Supplement - MitoQ

    The investigators will be measuring how an over-the-counter antioxidant supplement, called MitoQ, affects how blood flow responds to movement and exercise. Participants will orally ingest MitoQ during a baseline study visit as well as for 4 weeks at home.

    Dietary Supplement: MitoQ

  • Placebo comparator
    Placebo

    The investigators will compare the effects of MitoQ to a group receiving a placebo sugar pill. Participants will be randomized into receiving MitoQ or placebo. Participants will orally ingest the placebo pill during a baseline study visit as well as for 4 weeks at home.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementMitoQ

    MitoQ is an over the counter supplement that increases delivery to the mitochondria. Similar to studies performed in middle age/older adults and individuals with peripheral arterial disease, we will administer 1 single oral dose of 80mg of MitoQ or a placebo pill. We will examine the acute effects at the baseline vascular visit as well as chronically after 4 weeks of MitoQ supplementation at home.

  • Dietary supplementPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Ultrasound Measured Blood Flow during Passive Limb Movement (PLM)

    Microvascular response to passive limb movement

    Time frame: Change from baseline to after acute MitoQ (1 hour) and chronic MitoQ (4 weeks).

  2. Ultrasound Measured Blood Flow during Active Limb Contraction

    Hyperemic Response to Maximal Voluntary Contractions (MVCs)

    Time frame: Change from baseline to after acute MitoQ (1 hour) and chronic MitoQ (4 weeks).

Secondary outcomes

  1. Walking Speed

    Physical walking function

    Time frame: Change from baseline to after acute MitoQ (1 hour) and chronic MitoQ (4 weeks).

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — IDP is available upon reasonable request to the PI.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.

Of 112 non-industry phase 2 interventional studies under Stroke, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 23 months is below that.

Counting every sponsor, half of 132 studies reached it within 40 months; a quarter within 24 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938203
Responsible party
Matthew J. Durand (Professor, Medical College of Wisconsin) — Principal investigator
First posted
Nov 16, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Jennifer Nguyen
Contact
jnguyen@mcw.edu
414-955-5619
Alicen Whitaker-Hilbig, DPT, PhD
Contact
awhitakerhilbig@mcw.edu
Matthew Durand, PhD
principal investigator · Medical College of Wisconsin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion